A recent study from the Cleveland Clinic showed that genetic variants also play a significant role in the response to GLP-1 RAs, like semaglutide, for weight loss
The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage
Moreover, in addition to the direct action of GIP in adipose tissue to reduce serum triglyceride levels, GLP-1 may abolish the postprandial rise in triglyceride and free fatty acid concentrations by reducing intestinal absorption of dietary lipid, stemmed from the delayed gastric emptying (197, 198)
These products are not intended to diagnose, treat, cure, or prevent any disease
In clinical practice, weve seen patients experience meaningful results at subtherapeutic dosesjust more gradually and with better tolerability
Larsen, P